Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3074 Medullary Thyroid Carcinoma and DIPNECH: An Unexpected Association

Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour of the C-cells of thyroid gland. Diffuse idiopathic pulmonary neuroendocrine cells hyperplasia (DIPNECH) is a rare condition, thought to be primarily a neuroendocrine proliferative process which can develop into carcinoid tumours.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lima Ferreira J, Marques B, Elvas A, Simões de Carvalho F, Fonseca A,

Keywords: medullary thyroid cancer, DIPNECH, neuroendocrine tumour, carcinoid tumour, pulmonary nodules,

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids

Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Foll M

Authors: Alcala N, Dayton T, Mangiante L, Delhomme T, Tabone-Egling S,

Keywords: organoids, omics, evolution, lung, pancreas, bioinformatics,

#3046 Incidence of Neuroendocrine Neoplasms Reported in England 2015-2017

Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al). We report more recent data with more accurate coding (ICD-O-3).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: White B, Bouvier C, Genus T, Rous B, Srirajaskanthan R,

Keywords: Epidemiology, Neuroendocrine Neoplasia, Incidence, Prevalence, population data, histopathology,

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,